ALNA News and Press, Allena Pharmaceuticals Inc. From 11/07/19

Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria Phase 2 Study 206 Trial Demonstrates Substantial Plasma Oxalate Reduction in Patients with Enteric Hyperoxaluria and Advanced Chronic Kid...

If you don't know history, then you don't know anything. You are a leaf that doesn't know it is part of a tree . " - Michael Crichton Today, we look at a small 'Busted IPO' focusing on metabolic disorders. Company Overview: Allena Pharmaceuticals ( ALNA ) is a Newton, Massachusetts ba...

NEWTON, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...

Allena Pharmaceuticals ( ALNA -2.7% ) completes enrollment in a Phase 3 clinical trial, URIROX-1 , evaluating reloxaliase in patients with enteric hyperoxaluria, elevated levels of oxalate in the urine due to malabsorption of fat, a common consequence of intestinal resection or bypass s...

NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, ...

NEWTON, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, ...

Allena Pharmaceuticals ( ALNA ) is focused on rare metabolic and kidney disorders. Its lead drug, Reloxiliase, degrades oxalate in the gastrointestinal tract, and is being studied to treat enteric hyperoxaluria ( EH ). EH is a form of secondary hyperoxaluria that can cause nephrolithiasis (kid...

NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...

Allena Pharmaceuticals (NASDAQ: ALNA ): Q2 GAAP EPS of -$0.54 in-line. More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

-- Interim Data from Study 206 Demonstrated Substantial Treatment Effect in Patients with Enteric Hyperoxaluria and Advanced Chronic Kidney Disease, Including Robust Reductions in Both Urine and Plasma Oxalate -- -- Closed $10.0 Million Registered Direct Offering, Extending Cash Runwa...